However, using syngeneic immune complete cancer mouse models instead of transplanted xenografts, Liu et al. first demonstrated that the anti-tumor effects mediated by the CD47 blockade was mostly dependent on the tumor-specific CD8+ T cells. The gene discussed is CD8A; the disease is neoplasm.